Deal advances S1 Biopharma strategy for global commercialization of Lorexys. NEW YORK, Dec. 8, 2015 /PRNewswire/ — S1 Biopharma, Inc. a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women…
Read more ›
Mr. Sitchon will present an update on S1 Biopharma’s clinical stage development programs targeting treatment of diminished sexual desire in women and men. NEW YORK, Nov. 2, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for…
Read more ›
Expert on female sexual dysfunction disorder and CNS drug safety to outline challenges in development of combination therapies for CNS disorders. NEW YORK, Oct. 31, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual…
Read more ›
NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.…
Read more ›
JERSEY CITY, N.J., March 3, 2014 /PRNewswire/ — S1 Biopharma today announced its plan to initiate Phase 2a clinical trials in the third quarter of this year for Orexa (S1P-205), its first-in-class therapy to treat male Hypoactive Sexual Desire Disorder…
Read more ›